Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

Credit: fizkes / Shutterstock. US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, ...

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME) has been dosed. The company describes OCU200 as a “recombinant fusion protein that consists of ...

The patients were diagnosed with type 1 or type 2 diabetes mellitus ... A Cirrus HD-OCT 4000 (software Version 6.0) was used to obtain the macular images. The patients placed their chins in ...

by NHS England to integrate OCT into the NHS diabetic eye screening programme was, therefore, welcome. Indeed, it meant that about 60 000 referrals to secondary care could be avoided and that patients ...

DelveInsight's Diabetic Macular Edema Market report offers an ... causing them to leak fluid and leading to swelling in the macula. This swelling disrupts vision and can result in blurred or ...